Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
The identification of novel therapies, new strategies for combination of therapies, and repurposing of drugs approved for other indications are all important for continued progress in the fight against lung cancers. Antibodies that target immune checkpoints can unmask an immunologically hot tumor fr...
Enregistré dans:
Auteurs principaux: | Keller J Toral, Mark A Wuenschel, Esther P Black |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9d7801d876b04b58a06872bac8a15f68 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment
par: Tomohiro Takehara, et autres
Publié: (2021) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021) -
PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
par: Kensuke Kojima, et autres
Publié: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)